XOMA ROYALTY CORPORATION (XOMA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$40.170.00%
Close 2026-07-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · XOMA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 56.3% |
| Our one-year growth estimate | diamond | 5.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 50.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
XOMA — officer departure
Dated 2026-07-14
Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber, Matthew Perry: Multiple directors resigned as part of a Merger Agreement.
Why it matters: The CVR depends on the outcome of the Janssen case. A clear case update can show whether a payment remains possible.
Watch forA court filing or company update reports a ruling or settlement. It keeps a path to net proceeds open.
Also watch forA court filing or company update reports a final loss or dismissal with no net proceeds.
Why it matters: Ligand raised its 2026 adjusted EPS range after announcing the deal. The final result will test that higher target.
Watch forLigand reports 2026 adjusted EPS of at least $8.50 and keeps its stated deal benefits on track.
Also watch forLigand reports 2026 adjusted EPS below $8.50 or cuts its 2026 adjusted EPS range.
Why it matters: XOMA holders received a CVR tied to 75% of net proceeds from the Janssen case. A recovery could add value beyond the cash merger payment.
Supportive ifA court ruling or settlement yields net proceeds, and the CVR trust reports a payment to holders.
Worry ifThe case ends with no net recovery, or the CVR trust reports no payment after the case concludes.
Why it matters: Ligand said the XOMA deal adds seven marketed products and over 120 assets. Reported royalty revenue will show whether those assets add income.
Watch forLigand reports royalty revenue in or above its stated $225 million to $250 million 2026 range. It names XOMA assets as sources.
Also watch forLigand reports royalty revenue below $225 million for 2026 or says XOMA assets did not add the planned income.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$60 on $10,000 · ±0.6% | How much price usually moves either way. |
| Bad day | $500 loss on $10,000 · 5.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,237 loss on $10,000 · 42.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.